News

Recursion Pharmaceuticals Reports Strong Q2 2025 Results

Recursion Pharmaceuticals Reports Strong Q2 2025 Results

Recursion Pharmaceuticals Highlights Q2 2025 Financial Performance

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), a pioneering company in the field of TechBio, revealed its financial outcomes for the second quarter of 2025, reflecting a formidable path towards advancing medical solutions.

Business Updates

In its latest earnings call, Recursion accentuated the innovative capabilities of its Recursion OS platform, which is instrumental in identifying new drug candidates and understanding diverse patient demographics. Chris Gibson, the Co-Founder and CEO, emphasized the use of advanced technologies, like Boltz-2, to enhance drug discovery processes significantly.

Pipeline Evolution

REC-1245 and REC-617 Development

REC-1245, a promising candidate targeting replication stress in tumors, showcases compelling early data. It is being examined in the ongoing DAHLIA trial, focusing on solid tumors with particular DNA repair vulnerabilities. Meanwhile, REC-617 has transitioned into a combination dose escalation portion of the ELUCIDATE trial, aiming to provide groundbreaking treatment options for platinum-resistant ovarian cancer.

New Rights Acquisition

Recursion has secured full rights to REC-102, aiming for pivotal developments in treating hypophosphatasia. This potential oral treatment is set to initiate Phase 1 trials in the near future, expanding the company’s focus into rare genetic disorders.

Financial Summary

Cash Reserves and Funding

As of June 30, 2025, Recursion's cash, cash equivalents, and restricted cash stood at an impressive $533.8 million, reflecting robust financial health and a promising runway into 2027. The increase in research and development expenditures to $128.6 million compared to $73.9 million the previous year is primarily driven by strategic agreements, enhancing the company's capacity for drug development.

Revenue Performance

The company reported a total revenue of $19.2 million for Q2 2025, marking a notable increase from $14.4 million in Q2 2024. This growth reflects the company’s ability to harness collaboration agreements effectively.

Strategic Partnerships

Recursion and Sanofi continue to collaborate effectively on multiple oncology and immunology programs, with a synergy that has led to significant financial milestones, achieving $130 million in milestone payments thus far. Additionally, potential future collaborations aim to capitalize on the innovative capabilities of Recursion OS 2.0.

Looking Ahead

The company is positioned for further growth with various trials slated for additional data release in the second half of 2025. Key upcoming milestones include ongoing research studies for REC-617 and developments in REC-7735 targeting specific oncological pathways.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is dedicated to transforming drug discovery through its powerful AI-driven platform. The company integrates advanced technologies that allow it to conduct millions of experiments weekly, driving breakthroughs in how diseases are understood and treated. Founded as a response to the limitations in traditional drug development, Recursion is at the forefront of utilizing massive datasets for drug repositioning and discovery.

Contact Information

For further inquiries, reach out via email: Media@Recursion.com or Investor@Recursion.com.

Frequently Asked Questions

What is Recursion Pharmaceuticals?

Recursion Pharmaceuticals is a TechBio company focused on decoding biology to improve lives through innovative drug discovery technologies.

What are the latest financial results for Recursion?

In Q2 2025, Recursion reported total revenues of $19.2 million, marking significant growth year-over-year.

How is Recursion addressing drug development challenges?

They leverage advanced AI technologies to streamline the discovery process and enhance patient targeting in clinical trials.

What recent trials is Recursion conducting?

Recursion is actively enrolling patients in the DAHLIA trial for REC-1245 and the ELUCIDATE trial for REC-617.

Where can I find more about Recursion’s drug candidates?

Details on Recursion can be accessed on their official website or by contacting their media representatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Classys Rides Revenue Surge, Eyes China Growth

Updated Category News Views 93

Strong Numbers, But There's More to Unpack Nine months into 2026, Classys Inc. ain't exactly putting up shabby numbers. They've rolled in with KRW 275.7 billion like it was a stroll in the park, marking a sturdy 13% jump from last year. Yet, with all this, their operating profit has taken a 9.4% spill. It's a mixed bag, folks, and Classys is gearing up for a massive...

Continue Reading
AST SpaceMobile Faces Class Action Suit Deadline Looms

Updated Category News Views 95

AST SpaceMobile's Securities Class Action: The Lowdown When you roll the dice on a company like AST SpaceMobile, Inc. (NASDAQ: ASTS), you want to believe that you're betting on the stars. But lately, some investors might feel like they're seeing more darkness than starlight. Here's the kicker: AST SpaceMobile is staring down a securities fraud class action lawsuit. It's a...

Continue Reading
CSTS Backs Hong Kong's Nobel Sustainability Trust Put

Updated Category News Views 101

A New Chapter for CSTS and Sustainability Leadership Who would've thunk it? CSTS Enterprises, primarily known for its integrated media and sports ventures, is stepping into the sustainability arena as the Official Hospitality Partner for the Nobel Sustainability Trust Hong Kong Summit 2026. They're not just dipping a toe—they're diving headfirst into the pool, bringing...

Continue Reading
Fitness Career Platform's Big Ramp Up Sparks Buzz

Updated Category News Views 73

ISSA Career Connect Gains Industry Recognition In a world where finding that first job post-certification can be as brutal as a spin class in August, ISSA Career Connect seems to be offering a bit of a lifeline. This platform, already making some serious noise in the fitness industry, has just snagged a place as a finalist for App of the Year at the 2026 Beyond Activ...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 54

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
Cangzhou's Bold Bid: Inviting Global Media to Witness Growth

Updated Category News Views 104

From Cultural Riches to Industrial Powerhouse Ever been to Cangzhou? No? Well, the folks there want to change that narrative pronto. This coastal gem in northern China is throwing open its doors to the global media with a big ol’ invitation to see, explore, and spread the word about what makes this city tick. Part of the Seventh World Media Summit held in Beijing, this...

Continue Reading
Class Action Looms Over The Chemours Company

Updated Category News Views 112

Chemours Under Fire: What’s Happening? Here we are, in the thick of a legal storm surrounding The Chemours Company. A class-action lawsuit is underway, and it’s painting the company in a rather unflattering light. Now, if you snagged some of that NYSE:CC action between February 20, 2026, and August 4, 2026, there's a chance you’re caught in the crossfire. Per the...

Continue Reading
Webull Faces Class Action: Investors Eye Plaintiff Role

Updated Category News Views 97

Webull Under Fire: What's Happening? In a development that's got investors biting their nails, Webull (NASDAQ:BULL) finds itself caught up in a class action. The folks at Robbins LLP are waving a red flag, urging those who bought into Webull between the dates of April 26, 2025, and October 6, 2026, to sit up and take notice. A class action complaint claims that the...

Continue Reading
OI Investors Crack Down: Class Action Filing Looms

Updated Category News Views 124

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

Continue Reading
Palatin Prepares for FY27 Results Amid Market Curiosity

Updated Category News Views 34

Mark Your Calendars, Investors! Folks grumble about the mundane task of checking fiscal calendars, but without this intel, where are we? On November 17, 2026, Palatin Technologies (NASDAQ:PTN) is slated to release their Q1 Fiscal Year 2027 operating results bright and early, before most of us have even sipped our coffee. The buzz around these numbers is as electric as any...

Continue Reading

Top 5 Most Recently Viewed Articles

Coherent Corp. Showcases Innovative Transceiver Technologies

Updated Category News Views 157

Coherent Corp. Introduces Next-Generation Transceiver Modules Coherent Corp. (NYSE: COHR) has recently captured attention by launching two innovative transceiver modules at the European Conference on Optical Communication (ECOC) 2024. These two models, the 1.6T-DR8 and 800G-DR4 transceivers, are specifically designed to significantly enhance data transmission speeds and...

Continue Reading
Provident Financial Holdings Set to Release Earnings Soon

Updated Category News Views 167

Provident Financial Holdings, Inc. Earnings Release Announcement Provident Financial Holdings, Inc. (Nasdaq: PROV) has recently shared significant news that will cap off their financial quarter. As a holding company for Provident Savings Bank, F.S.B., they are poised to announce their third-quarter earnings soon. This update is eagerly anticipated by both institutional...

Continue Reading
Rivalry Corp. Secures Funds to Propel Future Growth and Innovation

Updated Category News Views 177

Rivalry Corp. Closes Initial Tranche of Private Placement Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), recognized as a leading sportsbook and iGaming operator dedicated to digital-first players, has reached a significant milestone by closing the first tranche of its non-brokered private placement. This announcement follows up...

Continue Reading
Understanding Insider Selling: Lessons From 3 Companies

Updated Category News Views 175

The Implications of Insider Selling Insider selling often triggers investor anxiety—but understanding the context is essential. Recently, sales at Dutch Bros, Monolithic Power Systems, and Palantir Technologies demonstrate that not all insider activity carries the same implications. In this article, we will break down the recent insider sales at these companies and...

Continue Reading
Quantum Corporation Faces Class Action Amid Financial Concerns

Updated Category News Views 173

Quantum Corporation Investors Urged to Act In light of recent challenges faced by Quantum Corporation, shareholders are advised to take note of significant developments that may impact their investments. As investors, it's crucial to stay informed, especially when issues arise that could potentially affect your financial standing. Financial Reporting Issues What Triggered...

Continue Reading